Avichal Kumar, Kamya Goyal, Vinay Pandit, MS Ashawat, Shammy Jindal
Avichal Kumar, Kamya Goyal, Vinay Pandit, MS Ashawat, Shammy Jindal*
Laureate Institute of Pharmacy, Kathog, Jwalamukhi, Himachal Pradesh, India -176031.
Volume - 13,
Issue - 10,
Year - 2020
The easy, simple and rapid spectrophotometric method (simultaneous equation method) have been generate for Halobetasol and Tazarotene drugs. These drugs are available in the form of gel, lotion, creams etc. The absorbance spectrum (?-max) of Halobetasol propionate was found to be 238nm and Tazarotene was found to be 352nm. The linearity of both Halobetasol and Tazarotene was found between 2-10µg/mL. The precision as well as accuracy of the developed method was performed statically. The reproducibility of the developed method was good, whereas recovery in %RSD is less than 1. From the analytical and statistical data of this developed method, it was concluded that this method is useful for laboratory spectrophotometric analysis of Halobetasol and Tazarotene from given formulation samples. The aim of doing this research work is due to the combination formulation phase-3 trial is in progress for both of these drugs. The Halobetasol is topical corticosteroid whereas Tazarotene is third generation topical retinoid. The purpose of the combinational formulation is to develop potent treatment for skin diseases like psoriasis. To decrease or avoiding the adverse effects of Halobetasol like skin roughness, skin dryness, itching, Tazarotene was selected in combination because of its counter effects on the adverse effect of Halobetasol.
Cite this article:
Avichal Kumar, Kamya Goyal, Vinay Pandit, MS Ashawat, Shammy Jindal. Simultaneous estimation of Halobetasol propionate and Tazarotene in pure and dosage form by using UV-Visible Spectrophotometric method. Research J. Pharm. and Tech. 2020; 13(10):4711-4714. doi: 10.5958/0974-360X.2020.00829.X
1. Andrew LB, Richare AB, Jeffrey WH, Mark PL. Emerging therapeutic targets in psoriasis. Current Opinion in Pharmacology. 2004; 4: 306–310.
2. Mendonca CO, Burden AD. Current concepts in psoriasis and its treatment. Pharmacology and therapeutics. 2003; 99(2): 133-147.
3. Bozzuto G, Lingan A. Liposomes as nanomedical devices. International Journal of Nanomedicine. 2015; 10: 975.
4. Kc S, Karn D. Practical aspects in topical PUVAsol in dermatology: An experience ina teaching hospital. Kathmandu University Medical Journal. 2014; 12(4): 306-307.
5. Zayed MA, Abdel-Basset MH. Spectrophotometric micro determination of tretinoin isotretinoin using iodine and tazarotene micro determination via reaction with Rose-Bengal reagent. Egyptian Journal of Chemistry. 2018; 61(1): 143–153.
6. Weinstein GD. Tazarotene gel: efficacy and safety in plaque psoriasis. Journal of the American Academy of Dermatology. 1997; 37(2): S33-S38.
7. Gregoriou S, Kritsotaki E, Katoulis A, Rigopoulos D. Use of tazarotene foam for the treatment of acne vulgaris. Clinical, Cosmetic and Investigational Dermatology. 2014; 7: 165.
8. Rawat D, Gunjan A, Gupta M, Singh S, Pathak A. Spectrophotometric and validated RP-HPLC method for the estimation of retinod drug Tazarotene in gel formulation. Asian Journal of Pharmaceutical Education and Research. 2013; 2: 72-89.
9. Chopade VV, Tembhurkar NB, Jadhav SB, Chaudhari PD. Development and validation of a stability indicating assay method of Mefloquine HCI by using different stress degradation conditions. Journal of Pharmacy Research. 2012; 5:2631-2635.
10. Vincent N, Ramya DD, Vedha HB. Progress in psoriasis therapy via novel drug delivery systems. Dermatology reports. 2014; 6(1): 5451.
11. Fischer-Levancini C, Sanchez-Regana M, Llambí F, Collgros H, Expósito-Serrano V, Umbert-Millet P. Nail psoriasis: treatment with tazarotene 0.1% hydrophilic ointment. Actas Dermo-Sifiliográficas. 2012; 103(8): 725-728.
12. Patel MR, Patel RB, Parikh JR, Patel BG. Novel microemulsion-based gel formulation of tazarotene for therapy of acne. Pharmaceutical Development and Technology. 2016; 21(8): 921-932.